Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Diagnostics, resistance and clinical relevance of non-tuberculous mycobacteria unidentified at the species level by line probe assays: a bi-national study

M. Dohál, N. Wetzstein, M. Hromádková, S. Mäsiarová, EM. Rasmussen, P. Kunč, M. Škereňová, I. Porvazník, I. Solovič, S. Niemann, J. Hnilicová, J. Mokrý, V. Dvořáková, M. Diricks

. 2025 ; 24 (1) : 14. [pub] 20250217

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25009862

Grantová podpora
2167 Deutsche Forschungsgemeinschaft
23-05622S Czech Science Foundation
18-0084 Agentúra na Podporu Výskumu a Vývoja
1/0093/22 Vedecká Grantová Agentúra MŠVVaŠ SR a SAV
75010330 Grant of Ministry of Health, Czech Republic

OBJECTIVES: While the reported incidence of non-tuberculous mycobacterial (NTM) infections is increasing, the true prevalence remains uncertain due to limitations in diagnostics and surveillance. The emergence of rare and novel species underscores the need for characterization to improve surveillance, detection, and management. METHODS: We performed whole-genome sequencing (WGS) and/or targeted deep-sequencing using the Deeplex Myc-TB assay on all NTM isolates collected in Slovakia and the Czech Republic between the years 2019 to 2023 that were unidentifiable at the species level by the routine diagnostic line probe assays (LPA) GenoType CM/AS and NTM-DR. Minimal inhibitory concentrations against amikacin, ciprofloxacin, moxifloxacin, clarithromycin, and linezolid were determined, and clinical data were collected. RESULTS: Twenty-eight cultures from different patients were included, of which 9 (32.1%) met the clinically relevant NTM disease criteria. The majority of those had pulmonary involvement, while two children presented with lymphadenitis. Antimycobacterial resistance rates were low. In total, 15 different NTM species were identified, predominantly rare NTM like M. neoaurum, M. kumamotonense and M. arupense. Notably, clinically relevant M. chimaera variants were also identified with WGS and Deeplex-Myc TB, which, unlike other M. chimaera strains, appeared to be undetectable by LPA assays. Deeplex detected four mixed infections that were missed by WGS analysis. In contrast, WGS identified two novel species, M. celatum and M. branderi, which were not detected by Deeplex-Myc TB. Importantly, one of these novel species strains was associated with clinically relevant pulmonary disease. DISCUSSION: Our study demonstrates the clinical relevance of uncommon NTM and the effectiveness of targeted deep-sequencing combined with WGS in identifying rare and novel NTM species.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009862
003      
CZ-PrNML
005      
20250429134946.0
007      
ta
008      
250415s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12941-025-00781-z $2 doi
035    __
$a (PubMed)39962513
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Dohál, Matúš $u Biomedical Centre Martin, Jessenius Faculty of Medicine in Martin, Comenius University, Bratislava, Slovakia. matus.dohal@uniba.sk
245    10
$a Diagnostics, resistance and clinical relevance of non-tuberculous mycobacteria unidentified at the species level by line probe assays: a bi-national study / $c M. Dohál, N. Wetzstein, M. Hromádková, S. Mäsiarová, EM. Rasmussen, P. Kunč, M. Škereňová, I. Porvazník, I. Solovič, S. Niemann, J. Hnilicová, J. Mokrý, V. Dvořáková, M. Diricks
520    9_
$a OBJECTIVES: While the reported incidence of non-tuberculous mycobacterial (NTM) infections is increasing, the true prevalence remains uncertain due to limitations in diagnostics and surveillance. The emergence of rare and novel species underscores the need for characterization to improve surveillance, detection, and management. METHODS: We performed whole-genome sequencing (WGS) and/or targeted deep-sequencing using the Deeplex Myc-TB assay on all NTM isolates collected in Slovakia and the Czech Republic between the years 2019 to 2023 that were unidentifiable at the species level by the routine diagnostic line probe assays (LPA) GenoType CM/AS and NTM-DR. Minimal inhibitory concentrations against amikacin, ciprofloxacin, moxifloxacin, clarithromycin, and linezolid were determined, and clinical data were collected. RESULTS: Twenty-eight cultures from different patients were included, of which 9 (32.1%) met the clinically relevant NTM disease criteria. The majority of those had pulmonary involvement, while two children presented with lymphadenitis. Antimycobacterial resistance rates were low. In total, 15 different NTM species were identified, predominantly rare NTM like M. neoaurum, M. kumamotonense and M. arupense. Notably, clinically relevant M. chimaera variants were also identified with WGS and Deeplex-Myc TB, which, unlike other M. chimaera strains, appeared to be undetectable by LPA assays. Deeplex detected four mixed infections that were missed by WGS analysis. In contrast, WGS identified two novel species, M. celatum and M. branderi, which were not detected by Deeplex-Myc TB. Importantly, one of these novel species strains was associated with clinically relevant pulmonary disease. DISCUSSION: Our study demonstrates the clinical relevance of uncommon NTM and the effectiveness of targeted deep-sequencing combined with WGS in identifying rare and novel NTM species.
650    _2
$a lidé $7 D006801
650    12
$a netuberkulózní mykobakterie $x účinky léků $x genetika $x izolace a purifikace $7 D009170
650    12
$a atypické mykobakteriální infekce $x mikrobiologie $x diagnóza $7 D009165
650    12
$a mikrobiální testy citlivosti $7 D008826
650    _2
$a mužské pohlaví $7 D008297
650    12
$a sekvenování celého genomu $7 D000073336
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    12
$a antibakteriální látky $x farmakologie $7 D000900
650    _2
$a dospělí $7 D000328
650    _2
$a dítě $7 D002648
650    _2
$a senioři $7 D000368
650    _2
$a mladiství $7 D000293
650    _2
$a vysoce účinné nukleotidové sekvenování $7 D059014
650    _2
$a předškolní dítě $7 D002675
650    _2
$a bakteriální léková rezistence $7 D024881
650    _2
$a genotyp $7 D005838
650    _2
$a klinická relevance $7 D000092522
651    _2
$a Česká republika $7 D018153
651    _2
$a Slovenská republika $x epidemiologie $7 D018154
655    _2
$a časopisecké články $7 D016428
700    1_
$a Wetzstein, Nils $u Molecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany $u German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany $u Department of Internal Medicine, Infectious Diseases, Goethe University, University Hospital, Frankfurt, Germany
700    1_
$a Hromádková, Michaela $u National Institute of Public Health, Prague, Czech Republic
700    1_
$a Mäsiarová, Simona $u Department of Pharmacology, Jessenius Faculty of Medicine in Martin, Comenius University, Bratislava, Slovakia
700    1_
$a Rasmussen, Erik M $u International Reference Laboratory of Mycobacteriology, Statens Serum Institut, Copenhagen, Denmark
700    1_
$a Kunč, Peter $u Clinic of Pediatric Respiratory Diseases and Tuberculosis, National Institute of Pediatric Tuberculosis and Respiratory Diseases, Dolny Smokovec, Jessenius Faculty of Medicine in Martin, Comenius University, Bratislava, Slovakia $u Department of Pathological Physiology, Jessenius Faculty of Medicine in Martin, Comenius University, Bratislava, Slovakia
700    1_
$a Škereňová, Mária $u Biomedical Centre Martin, Jessenius Faculty of Medicine in Martin, Comenius University, Bratislava, Slovakia
700    1_
$a Porvazník, Igor $u National Institute of Tuberculosis Lung Diseases and Thoracic Surgery, Vyšné Hágy, Slovakia $u Faculty of Health, Catholic University, Ružomberok, Slovakia
700    1_
$a Solovič, Ivan $u National Institute of Tuberculosis Lung Diseases and Thoracic Surgery, Vyšné Hágy, Slovakia $u Faculty of Health, Catholic University, Ružomberok, Slovakia
700    1_
$a Niemann, Stefan $u Molecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany $u German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany
700    1_
$a Hnilicová, Jarmila $u Department of Genetics and Microbiology, Faculty of Science, Charles University, Prague, Czech Republic
700    1_
$a Mokrý, Juraj $u Department of Pharmacology, Jessenius Faculty of Medicine in Martin, Comenius University, Bratislava, Slovakia
700    1_
$a Dvořáková, Věra $u National Institute of Public Health, Prague, Czech Republic. vera.dvorakova@szu.cz
700    1_
$a Diricks, Margo $u Molecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany $u German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany
773    0_
$w MED00008163 $t Annals of clinical microbiology and antimicrobials $x 1476-0711 $g Roč. 24, č. 1 (2025), s. 14
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39962513 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134942 $b ABA008
999    __
$a ok $b bmc $g 2311323 $s 1246943
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 24 $c 1 $d 14 $e 20250217 $i 1476-0711 $m Annals of clinical microbiology and antimicrobials $n Ann Clin Microbiol Antimicrob $x MED00008163
GRA    __
$a 2167 $p Deutsche Forschungsgemeinschaft
GRA    __
$a 23-05622S $p Czech Science Foundation
GRA    __
$a 18-0084 $p Agentúra na Podporu Výskumu a Vývoja
GRA    __
$a 1/0093/22 $p Vedecká Grantová Agentúra MŠVVaŠ SR a SAV
GRA    __
$a 75010330 $p Grant of Ministry of Health, Czech Republic
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace